SCHEMBL7130591

SCHEMBL7130591

CCCCCc1n[nH]c2ccc(Oc3c(C)cc(N)cc3C)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 3/20 0.44
THRB P10828 3/20 0.44
LRRK2 Q5S007 1/20 0.35
TTK P33981 2/20 0.34
HTR1A P08908 6/20 0.34
HTR1D P28221 6/20 0.34
HTR1B P28222 6/20 0.34
GHSR Q92847 1/20 0.34
MAPT P10636 2/20 0.34
MAPK1 P28482 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HTR2A P28223 1/20 0.34
CYP2C19 P33261 1/20 0.34
CDC7 O00311 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7138299 0.92 THRA (0.38) THRATHRBLRRK2TTKHTR1A
SCHEMBL7138045 0.86 THRA (0.48) THRATHRBLRRK2TTKHTR1A
SCHEMBL7138386 0.84 THRA (0.43) THRATHRBLRRK2GHSRMAPT
SCHEMBL7131426 0.81 GSK3B (0.37) THRATHRBLRRK2TTKHTR1A
SCHEMBL7230331 0.81 THRB (0.51) THRATHRBTTKGSK3BMAPK8
SCHEMBL7133145 0.81 THRA (0.60) THRATHRBTTKMAPK8
SCHEMBL7135882 0.79 THRA (0.43) THRATHRBTTKHTR1AHTR1B
SCHEMBL7135874 0.79 THRA (0.73) THRATHRB
SCHEMBL7133369 0.79 THRA (0.49) THRATHRBTTKDPP4MAPK8
SCHEMBL7225729 0.79 THRA (0.53) THRATHRBTTKMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608049-B2 Indazoles BAYER AKTIENGESELLSCHAFT (DE) 2003-08-19 US disclosed
EP-1324987-A1 INDAZOLES WITH THYROID HORMON LIKE ACTIVITY, A PROCESS FOR ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS Bayer Aktiengesellschaft (DE) 2003-07-09 EP disclosed
US-20020193610-A1 Indazoles BAYER AKTIENGESELLSCHAFT (DE) 2002-12-19 US disclosed
WO-2002022586-A1 INDAZOLES HAVING AN ACTION SIMILAR TO THAT OF A THYROID HORMONE, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE IN MEDICAMENTS BAYER AKTIENGESELLSCHAFT (DE) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193610-A1 Indazoles CYP3A43, CYP3A5, CYP3A4 THRA 3910/4885THRB 4025/4885LRRK2 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.